"Gazeta Giełdy Parkiet" in the publication from 26 August stresses the Group's interest in the clinical trials segment. After the company took over Clinport in March 2015, it continues to invest in the segment. The purchase of 64.3% shares of Bioscience company is the investment in a company that plans and executes clinical trials on new medicaments and medical products - informs the daily "Parkiet".

The daily cites Grzegorz Dzik, NEUCA's Vice-president of the Board, who stresses, latest acquisitions are an element of synergy construction between core company's activity and other sectors of broadly defined healthcare market. At the same time, he does not exclude further possible investments in that area.

distributed by